Can we select NSCLC patients for immune checkpoint therapy?

22 / 38

Rangachari – JTO 2018 * Sabari – ASCO 2017 * Dudnik – WCLC 2017 * Soo- Lung Cancer 2018 * Spigel – ASCO 2016
Oncogenic addicted NSCLC and TMB
PD-L1 ≥ 50% in: ~40% MET exon 14, BRAF V600E, but only 5% in EGFR, ALK, ROS1.